Among them, several genes have been identified as PCa therapeutic targets including VEGFA (vascular endothelial growth factor A), PTEN (phosphatase and tensin homolog), PIP5K1A (phosphatidylinositol-4-phosphate 5-kinase type 1 alpha), and CDK1 (cyclin-dependent kinase 1) (Semenas et al., 2014; Koryakina et al., 2015; Sarwar et al., 2016; Mateo et al., 2017; Cereda et al., 2018). The gene discussed is PIP5K1A; the disease is posterior cortical atrophy.